Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and Erlotinib in Refractory Colorectal Cancer
NCT00784667Phase 2Unknown
- Sponsor
- Austin Health
- Start
- Oct 2008
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in metastatic colorectal cancer (mCRC), sponsored by Austin Health. Status: unknown.
02
Drugs
erlotinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00784667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00784667.